Placebo for AMG 133 (maridebart cafraglutide)
Sponsors
Amgen Inc.
Conditions
Chronic Weight Management
Phase 3
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight (MARITIME-2)
Active, not recruitingCTIS2024-515523-11-00
Start: 2025-06-09Target: 404Updated: 2025-09-25
A Phase 3, Randomized, Double-Blind Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Participants with Obesity or Overweight with Type 2 Diabetes Mellitus
Not yet recruitingCTIS2025-524788-19-00
Target: 335Updated: 2026-09-22